Dana-Farber Cancer Institute: Improved Progression-Free Survival in Patients With Multiple Myeloma Following Three-Drug Therapy With Autologous Stem Cell Transplant
June 06, 2022
June 06, 2022
BOSTON, June 6 (TNSjou) -- The Dana-Farber Cancer Institute issued the following news release:
Patients with multiple myeloma who have been treated with a three-drug combination therapy have a growing number of choices for subsequent treatment. Results of a new study led by researchers at Dana-Farber Cancer Institute can help patients and their physicians weigh benefits and risks of each option.
The study, being presented today at the Annual Meeting of the American Soci . . .
Patients with multiple myeloma who have been treated with a three-drug combination therapy have a growing number of choices for subsequent treatment. Results of a new study led by researchers at Dana-Farber Cancer Institute can help patients and their physicians weigh benefits and risks of each option.
The study, being presented today at the Annual Meeting of the American Soci . . .